Patents by Inventor Julia CORONELLA

Julia CORONELLA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • DRUG CONJUGATES OF cMET MONOCLONAL BINDING AGENTS, AND USES THEREOF
    Publication number: 20250032632
    Abstract: Presented herein are novel monoclonal cMET binding agents that are conjugated to pyrrolobenzodiazepine toxins, composition thereof and uses thereof for the treatment of cancer.
    Type: Application
    Filed: August 12, 2024
    Publication date: January 30, 2025
    Inventors: Julia CORONELLA, Marco GYMNOPOULOS, Vincent BLOT, Ryo FUJITA, Roland NEWMAN
  • Drug conjugates of cMET monoclonal binding agents, and uses thereof
    Patent number: 12060427
    Abstract: Presented herein are novel monoclonal cMET binding agents that are conjugated to pyrrolobenzodiazepine toxins, composition thereof and uses thereof for the treatment of cancer.
    Type: Grant
    Filed: March 27, 2019
    Date of Patent: August 13, 2024
    Assignee: MITSUBISHI TANABE PHARMA CORPORAT
    Inventors: Julia Coronella, Marco Gymnopoulos, Vincent Blot, Ryo Fujita, Roland Newman
  • BI-SPECIFIC BINDING AGENTS TARGETING SYNDECAN-1 AND FIBROBLAST GROWTH FACTOR RECEPTOR
    Publication number: 20220249679
    Abstract: Presented herein, in certain embodiments, are bi-specific binding agents comprising an antibody portion that binds specifically to syndecan-1 and a Fynomer portion that binds specifically to a Fibroblast Growth Factor Receptor 3 (FGFR3), compositions thereof and uses thereof for treating a neoplasm.
    Type: Application
    Filed: October 1, 2019
    Publication date: August 11, 2022
    Inventors: Julia CORONELLA, Robyn RICHARDSON, Anjuli TIMMER, Roland NEWMAN, Marco GYMNOPOULOS
  • CMET monoclonal binding agents, drug conjugates thereof and uses thereof
    Patent number: 11299547
    Abstract: Presented herein, in certain embodiments, are compositions comprising monoclonal binding agents that specifically bind to the extracellular domain of cMET and uses thereof.
    Type: Grant
    Filed: September 28, 2017
    Date of Patent: April 12, 2022
    Assignee: MITSUBISHI TANABE PHARMA CORPORATION
    Inventors: Julia Coronella, Vincent Blot, Marco Gymnopoulos, Anjuli Timmer, Ryo Fujita, Roland Newman
  • Syndecan-1 (CD138) binding agents and uses thereof
    Patent number: 11242403
    Abstract: Presented herein, in certain embodiments, are compositions comprising binding agents that specifically bind to syndecan-1 and uses thereof.
    Type: Grant
    Filed: April 25, 2018
    Date of Patent: February 8, 2022
    Assignee: MITSUBISHI TANABE PHARMA CORPORATION
    Inventors: Julia Coronella, Robyn Richardson, Anjuli Timmer, Roland Newman
  • DRUG CONJUGATES OF cMET MONOCLONAL BINDING AGENTS, AND USES THEREOF
    Publication number: 20210163604
    Abstract: Presented herein are novel monoclonal cMET binding agents that are conjugated to pyrrolobenzodiazepine toxins, composition thereof and uses thereof for the treatment of cancer.
    Type: Application
    Filed: March 27, 2019
    Publication date: June 3, 2021
    Inventors: Julia CORONELLA, Marco GYMNOPOULOS, Vincent BLOT, Ryo FUJITA, Roland NEWMAN
  • SYNDECAN-1 (CD138) BINDING AGENTS AND USES THEREOF
    Publication number: 20200181278
    Abstract: Presented herein, in certain embodiments, are compositions comprising binding agents that specifically bind to syndecan-1 and uses thereof.
    Type: Application
    Filed: April 25, 2018
    Publication date: June 11, 2020
    Inventors: Julia CORONELLA, Robyn RICHARDSON, Anjuli TIMMER, Roland NEWMAN
  • CMET MONOCLONAL BINDING AGENTS, DRUG CONJUGATES THEREOF AND USES THEREOF
    Publication number: 20190330354
    Abstract: Presented herein, in certain embodiments, are compositions comprising monoclonal binding agents that specifically bind to the extracellular domain of cMET and uses thereof.
    Type: Application
    Filed: September 28, 2017
    Publication date: October 31, 2019
    Inventors: Julia CORONELLA, Vincent BLOT, Marco GYMNOPOULOS, Anjuli TIMMER, Ryo FUJITA, Roland NEWMAN
  • Antibody fab fragments specific for breast cancer
    Publication number: 20040151724
    Abstract: Human antibody fragments (Fab 14.6.19 and Fab 14.6.20) including polynucleotides and amino acids (SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5 and SEQ ID NO: 6) that identify them. Both Fabs are fully human, are affinity matured in vivo, are highly specific for breast cancer, and target an antigen that is immumogenic in vivo. Thus, each Fab may be a useful clinical reagent for diagnosis or therapy of breast cancer and may also lead to the discovery of a novel immunogenic and tumor specific breast cancer antigen.
    Type: Application
    Filed: October 30, 2003
    Publication date: August 5, 2004
    Inventor: Julia Coronella-Wood